Genocea Biosciences June 15th Short Interest Update

Genocea Biosciences (NASDAQ:GNCA) has witnessed a drop of 4.8% or 247,720 shares in its short figure. The short interest diminution took it from 5,119,244 on May 31,2016 to 4,871,524 on June 15,2016. In terms of floated shares, the short interest was calculated to be 23.7%. The days to cover are 14 given that the daily volume averaged 350,841 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Genocea Biosciences (NASDAQ:GNCA): The stock opened at $4.08 on Friday but the bulls could not build on the opening and the stock topped out at $4.47 for the day. The stock traded down to $4.08 during the day, due to lack of any buying support eventually closed down at $4.20 with a loss of -10.17% for the day. The stock had closed at $4.67 on the previous day. The total traded volume was 2,995,914 shares.

The company shares have dropped -67.61% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $16.18 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $4.04 and the 200 Day Moving Average price is recorded at $4.50.

Genocea Biosciences (NASDAQ:GNCA) has climbed 13.07% in the past week and advanced 5.4% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 14.95% and the outperformance has advanced to 8.59% for the last 4 weeks period.

Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies to address diseases with unmet needs. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria. It also creates a library of every protein in the proteome of the pathogen of interest. It uses ATLAS as a throughput engine to screen human T cells to identify relevant T cell vaccine antigens.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.